Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Recent phase III trials have proven the fact that adding bevacizumab to irinotecan plus infusional 5-fluorouracil (5-FU)/leucovorin (LV) should be preferred as a first-line treatment for metastatic colorectal cancer (mCRC). But, since the data regarding bevacizumab administered together with capecitabin, an oral fluoropyrimidine, and irinotecan in patients with mCRC is limited, we aimed to analyse the efficacy and safety of bevacizumab with capecitabine plus irinotecan (BEV-CAPIRI) regimen in mCRC patients. Records of patients treated with BEV-CAPIRI regimen between January 2005 and March 2008 were reviewed. Efficacy data regarding response rates (RR) as well as safety data were collected. Progression free survival (PFS) and overall survival (OS) analyses were done by using the Kaplan–Meier method. A total number of 53 metastatic colorectal cancer patients were treated with BEV-CAPIRI regimen. The median age of this population was 57.3 ± 11.5 (range 29–78). The treatment was well tolerated. The RR was 43.3%, while 30.1% of the patients achieved stable disease (SD). Median PFS and OS were 12.6 ± 1.4 and 20.6 ± 1.7 months, respectively. However, median OS was 21.3 months for male and 14.6 months for female patients. In addition, median OS and PFS was 25.3 months and 16.2 months for the patients who received BEV-CAPIRI as first-line treatment, respectively, and for the other patients it was 15.2 months and 10.2 months, respectively. In conclusion, BEV-CAPIRI is an effective and well-tolerated alternative regimen for mCRC, leading to disease control in a vast majority of patients with mCRC.
- Cercek A, Saltz LB. First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents. Clin Colorectal Cancer. 2008;7(Suppl 2):47–51. CrossRef
- De Gramont A, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18(16):2938–47.
- Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy. 2008;28:23–30. CrossRef
- Uemura N, Yamada Y. FOLFIRI regimen for metastatic or recurrent colorectal cancer. Gan To Kagaku Ryoho. 2006;33(7):904–6.
- Delord JP, et al. Dose escalation, pharmacokinetic study of capecitabine (Xeloda), irinotecan (CPATİENT-11) in gastrointestinal tumors. Proc Am Soc Clin Oncol. 2002;21:A397.
- Kerr DJ, et al. A phase I/II study of CPATİENT-11 in combination with capecitabine as first line chemotherapy for metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol. 2002;21:A643.
- Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006;17:239–45. CrossRef
- Therasse P, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92:205–16. CrossRef
- Tol J, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563–72. CrossRef
- Hurwitz H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42. CrossRef
- Kabbinavar F, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol. 2003;21(1):60–5. CrossRef
- Kabbinavar FF, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: result of a randomized phase II trial. J Clin Oncol. 2005;23(16):3697–705. CrossRef
- Cartwright TH, Encarnacion C, Vukelja S, et al. A phase II open-label study of capecitabine in combination with irinotecan as first line treatment for mCRC. Gastrointestinal cancers symposium: current status and future direction for prevention and management, San Francisco, CA, Abstract 271, 2004.
- Patt YZ, Lin E, Liebman J, et al. Capecitabine plus irinotecan: a highly active first-line treatment for metastatic colorectal cancer (mCRC). Proc Am Soc Clin Oncol. 2004;23:A228.
- Bajetta E, et al. Randomized multicenter phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in mCRC. Cancer. 2004;100(2):279–87. CrossRef
- Ardavanis A, et al. Bevcizumab added to the irinotecan and capecitabine combination for advanced colorectal cancer: a well-tolerated, active and convenient regimen. Anticancer Res. 2008;28:3087–92.
- Moehler M, et al. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol. 2009;15(4):449–56. CrossRef
- Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer
Volume 27, Issue 3 , pp 585-591
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Metastatic colorectal cancer
- Industry Sectors
- Author Affiliations
- 1. Division of Medical Oncology, Tulay Aktas Oncology Hospital, Ege University School of Medicine, Bornova, 35100, Izmır, Turkey
- 2. Department of Public Health, Ege University School of Medicine, Bornova, Izmır, Turkey
- 3. Department of Radiation Oncology, SB Izmir Tepecik Training and Research Hospital, Izmir, Turkey